Humedix Co

Humedix Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Humedix Co (200670.KQ) as of Oct 17, 2026 is 71.71 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 107.18 % — a change of -33.10% (lower).

FCF Conversion

71.71 %

YoY

-33.10%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Humedix Co is 2025 71.71 % . FCF Conversion Rate (FCF/EBITDA) of Humedix Co was 2024 107.18 % . It decreases by -33.10% lower compared to the previous year.

The Humedix Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
117.52 KRW
Jan 1, 2019
42.97 KRW
Jan 1, 2020
40.24 KRW
Jan 1, 2021
60.03 KRW
Jan 1, 2022
146.41 KRW
Jan 1, 2023
88.05 KRW
Jan 1, 2024
107.18 KRW
Jan 1, 2025
71.71 KRW
The Humedix Co FCF Conversion history
YEARFCF ConversionYoY
71.71 %-33.10%
107.18 %+21.72%
88.05 %-39.86%
146.41 %+143.90%
60.03 %+49.16%
40.24 %-6.34%
42.97 %-63.44%
117.52 %-231.96%
-89.06 %-38.13%
-143.94 %-2,020.04%
7.50 %-91.74%
90.77 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humedix Co Stock analysis

What does Humedix Co do? Humedix Co Ltd, identified by the ticker symbol 200670.KQ and ISIN KR7200670008, is a South Korean enterprise operating within the health care sector, specifically in the pharmaceuticals industry. Headquartered in Seongnam, the company has established itself as a specialized manufacturer and distributor of medical devices and therapeutic products. The firm's core business activities revolve around the production and sale of hyaluronic acid-based medical devices, which are widely utilized in various clinical applications, as well as specialized products designed for the treatment of arthritis. This focus on hyaluronic acid highlights the company's commitment to addressing significant health challenges related to joint health and mobility, catering to a growing demographic concerned with degenerative joint conditions. The company maintains a workforce of 338 full-time employees, reflecting its operational scale and capacity to manage both domestic and international supply chains. Humedix achieved a significant milestone in its corporate history by conducting its initial public offering on December 26, 2014. This event marked the company's entry into the public markets, providing it with increased visibility and access to capital for potential expansion and research initiatives. Since its public listing, Humedix has continued to refine its product portfolio and strengthen its market presence. Geographically, the company distributes its products not only within the domestic South Korean market but also extends its reach to overseas markets. This dual-market strategy allows Humedix to diversify its revenue streams and mitigate risks associated with regional economic fluctuations. By serving both local and international customers, the company leverages its manufacturing capabilities to meet diverse regulatory and consumer demands across different regions. The headquarters in Seongnam serves as the central hub for its administrative, research, and distribution operations, ensuring efficient coordination of its business activities. Through its dedicated efforts in developing hyaluronic acid-based solutions, Humedix Co Ltd continues to play a role in the broader health care ecosystem, providing essential medical devices and treatments that improve patient outcomes. The company's website, http://www.humedix.com/, serves as a primary resource for stakeholders seeking further information about its products, corporate governance, and financial performance. As the health care landscape evolves, Humedix remains focused on its core competencies in pharmaceutical manufacturing and medical device distribution, aiming to sustain growth and innovation in its specialized field. Humedix Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humedix Co stock

FCF Conversion Rate (FCF/EBITDA) of Humedix Co is 71.71 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Humedix Co changed from 107.18 % to 71.71 %, representing a -33.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Humedix Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Humedix Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Humedix Co

All Key Metrics — Humedix Co